Comparison of the efficacy in prevention of hepatitis B virus recurrence after liver transplantation between HBIG and lamivudine

Transplantation Proceedings

Volumn 33, Issue 7-8, 2001, Pages 3643-3644

  Lee, K W ^a   Lee, S K ^a,b   Joh, J W ^a   Kim, S J ^a   Park, J H ^a   Chon, S E ^a   Choi, S H ^a   Heo, J S ^a   Paik, S W ^a   Koh, K W ^a   Lee, J H ^a   Choi, M S ^a   Kim, Y I ^a   Lee, B B ^a  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HEPA BIG; HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; SURVIVAL RATE; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TIME FACTORS;

EID: 0035679820     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(01)02567-2     Document Type: Article

References (5)

1. Lee SK, Park JH, Joh JW, et al: Transplant Proc 32:2248, 2000
2. Langrehr JM, Lemmens HP, Keck H, et al: Transplant Proc 27:1215, 1995
3. Ghany MG, Ayola B, Villamil FG, et al: Hepatology 27:213, 1998
4. Bartholomew MM, Jansen RW, Jeffers LJ, et al: Lancet 349:20, 1997
5. McCaughan GW, Spencer J, Koorey D, et al: Liver Transpl Surg 5:512, 1999